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Abstract
Background: It is estimated that global dementia rates will more than triple by 2050 and result in a staggering
economic burden on families and societies. Dementia carries significant physical, psychological and social challenges
for individuals and caregivers. Informal caregiving is common and increasing as more people with dementia are being
cared for at home instead of in nursing homes. Caregiver burden is associated with lower perceived health, lower
social coherence, and increased risk of morbidity and mortality. The aim of this trial is to evaluate the effects of
information and communication technology (ICT) on caregiver burden among informal caregivers of people with
dementia by reducing the need for supervision.
Methods/design: This randomized controlled trial aims to recruit 320 dyads composed of people with dementia living
in community settings and their primary informal caregivers. In the intervention group, people with dementia will have
a home monitoring kit installed in their home while dyads in the control group will receive usual care. The ICT kit
includes home-leaving sensors, smoke and water leak sensors, bed sensors, and automatic lights that monitor the
individual’s behavior. Alerts (text message and/or phone call) will be sent to the caregiver if anything unusual occurs.
All study dyads will receive three home visits by project administrators who have received project-specific training in
order to harmonize data collection. Home visits will take place at enrollment and 3 and 12 months following
installation of the ICT kit. At every home visit, a standardized questionnaire will be administered to all dyads to assess
their health, quality of life and resource utilization. The primary outcome of this trial is the amount of informal care
support provided by primary informal caregivers to people with dementia.
Discussion: This is the first randomized controlled trial exploring the implementation of ICT for people with dementia
in a large sample in Sweden and one of the first at the international level. Results hold the potential to
inform regional and national policy-makers in Sweden and beyond about the cost-effectiveness of ICT and its
impact on caregiver burden.
Trial Registration: ClinicalTrials.gov, NCT02733939. Registered on 10 March 2016.
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Background
Worldwide, 47.5 million people are living with dementia,
and it is estimated that their number will double by
2030 and more than triple by 2050 as a result of the
world’s aging population [1]. Dementia has a dramatic
impact on individuals but also places a staggering bur-
den on families and societies, which makes it a public
health priority [2]. In Sweden, there are approximately
160,000 people who are diagnosed with some form of
dementia. During the last 15 years, the actual number of
people with a dementia diagnosis has increased, and ap-
proximately 25,000 new dementia cases are diagnosed
every year in Sweden [3] with Alzheimer’s disease being
the most common diagnosis. The majority of people
with dementia live in their own homes despite consider-
able disability. Thus, the costs to municipalities for
home care services, housing adaptations and technical
devices have increased [4].
Informal caregiving, provided by relatives or friends,
has increased along with the prevalence of the disease
and more people with dementia are being cared for at
home instead of in nursing homes. A study by Nordberg
and colleagues [5] suggested that the amount of informal
care that people with dementia receive is greater than
the amount of formal care (6 h/day compared to 1 h/
day) even in the generous Scandinavian welfare systems.
In other European countries, such as Italy, the number
of hours of care provided by primary informal caregivers
has been estimated to be as high as 50 h per week,
which includes direct care provision and supervision
activities [6]. There are different methods to evaluate the
economic impact of the time spent in care activities by
informal caregivers, and this leads to a clear heterogeneity
of research findings [7]. However, all available figures sug-
gest a significantly high societal burden. In Sweden, which
has fewer than 9 million inhabitants, the National Board
of Health and Welfare estimated that the annual cost of
dementia was about SEK62.9 billion (USD7.34 billion) or
approximately SEK400,000 (USD46,660) per person with
dementia, of which the societal cost reached approxi-
mately SEK10 billion (USD1.17 billion) [4]. The size of
such burden and its likely increase over the next few years
urges policy-makers and professionals to tackle this
phenomenon with new and innovative measures to ensure
the sustainability of the existing welfare states [1].
While a cure for dementia is not available yet, an area
of interest for professionals and policy-makers is support
for caregivers. As a consequence of their intensive and
lengthy engagement (a person with dementia can live up
to 20 years after diagnosis) [8], dementia caregivers are
at risk of experiencing anxiety and stress, which leads to
a higher rate of mortality compared to their noncare-
giver counterparts [9]. Informal caregivers with high
caregiver burden report lower perceived health and
higher care services and drug utilization compared to
caregivers with lower burden [10]. Interventions that
support caregivers of people with dementia do not only
hold the potential to reduce the burden but could also
lead to beneficial effects for the people with dementia,
e.g., delaying nursing home placements and reducing the
use of antipsychotic medications [11]. Several innovative
strategies have been tested to reduce the burden of care:
providing practical assistance, education [12], role-
training interventions [13], family intervention programs
[14], and psychoeducational interventions [15]. Results
of these approaches are inconsistent, but it has been
suggested that multicomponent interventions that com-
bine different strategies have the greatest impact on
reducing care burden [12, 16, 17].
In recent years, multicomponent interventions that
include a combination of innovative technologies and
more “traditional” care services have become increas-
ingly popular in the field of dementia care. As caregivers’
supervision time, necessary to prevent dangerous and
harmful events for the person with dementia, constitutes
the largest share of informal caregiving, new technologies
for environmental safety and control can potentially
reduce the time needed for supervision. However, studies
in this area have rarely been well-designed epidemiological
studies, but they have rather tended to be stand-alone
pilots, qualitative studies or uncontrolled trials based on
convenience samples, generally conducted by researchers
in the technology field [18].
The UP-TECH project was a recent study about the
impact of new technologies for dementia caregivers, in-
volving care staff, engineers, epidemiologists and health
economists, which developed and tested a prototypical
ICT solution combined with a case-management inter-
vention in more than 100 households in Italy [19]. UP-
TECH used home monitoring kits to monitor adverse
and dangerous events (e.g., smoke, water leaks, unex-
pected opening of doors or windows, prolonged absence
from bed) through a wireless network and a control unit
that sent alarms to the caregivers via mobile phone [20].
Preliminary results of the UP-TECH study have been
promising, and user satisfaction with the solution was
high [21]. Another relevant study is the ATTILA trial in
England [22]. ATTILA uses assistive technology and tel-
ecare (ATT) to support independent living at home for
people with dementia. The hypothesis of the study is
that people with dementia who receive ATT will be less
likely to go into institutional care than those who receive
equivalent community services without ATT. Results for
this study are not yet available as the study is still ongoing.
The TECH@HOME study builds on the experiences of
the UP-TECH study and will test the impact of a newly
designed technology to support caregivers of people with
dementia who are still living in the community, in terms
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of effectiveness and cost-effectiveness. We hypothesize
that technologies can substitute for some of the time
caregivers spend in supervision and monitoring activities
for people with dementia. The decreased time is ex-
pected to reduce the caregiver burden, and thus result in




TECH@HOME is a randomized controlled trial to test
the effectiveness of an innovative technological interven-
tion among people with dementia and their primary in-
formal caregivers in Sweden. The intervention will last
12 months. A total of 320 dyads, including people with
dementia and their primary informal caregivers (640
participants in total), will be recruited. These dyads will
be randomized either into an intervention or a control
group (see Fig. 1 for the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) figure and
for the complete SPIRIT Checklist see Additional file 1).
All dyads, both the intervention and control groups, will
receive three home visits (at baseline and 3 and 12 months
after enrollment) from a dementia nurse in charge of data
collection.
In the intervention group, besides usual care, the
people with dementia will have a technological home
monitoring kit installed in their home (as described
under the “Intervention tested” section) while dyads in
the control group will only receive usual care. Usual care
for people with dementia in Southern Sweden can vary.
In the target area, people with dementia usually receive
Fig. 1 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure of TECH@HOME
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comparable pharmaceutical treatment depending on the
type of dementia, as prescribed by a general practitioner
or a specialist at a memory clinic. Patients of memory
clinics receive regular follow-ups depending on the type
of diagnosis and on-going treatment response, while the
majority of people with dementia are treated and moni-
tored at a primary health care center and by the municipal
health care services. Social workers from the municipality
(“Biståndshandläggaren”) where the person resides, to-
gether with district nurses, have a meaningful role in
tailoring the care plan by mediating access to other care
services such as respite care homes, home help, and
(dementia) nurse home visits. Use of such services
depends on the specific needs of the person with demen-
tia, which can also be unrelated to dementia, but rather
dependent upon concomitant health and social issues.
Intervention tested
The intervention includes the installation and use of a
technical monitoring kit in the home for 12 months.
The home monitoring kit includes devices that are easy
to use and do not require significant technical expertise
for installation and maintenance. The kits will be com-
posed of a control unit and a set of sensors that immedi-
ately notify caregivers, through their phones, of any
potential risks for the person with dementia. The kit will
have home-leaving sensors, bed-occupancy sensors, smoke
and water leak sensors, automatic lights, and other inter-
active functions. These devices will be connected to a
single-board microcontroller that will transmit alarm mes-
sages to the caregivers in case of need. The monitoring kits
will be assembled by an external contractor and installed
by a handyman who will also train the caregivers about
their use (see Fig. 2). The handyman will be trained and
receive a manual on how to provide a standardized intro-
duction to all caregivers, who will be probed to ask for
additional information. Written information for users will
be developed in collaboration with caregivers, followed by
a subsequent field test.
Functionality of the kit
In case of potentially harmful or dangerous situations, the
control unit will notify the selected phone number with a
text message and/or phone call. If the caregiver does not
answer, the control unit will contact alternate numbers in
the order specified (maximum six home and mobile phone
numbers chosen by the caregivers). The home monitoring
kit will notify the caregivers about potentially dangerous
situations such as when the person with dementia:
 leaves the home without notice, since this might
occur in a moment of disorientation and the person
might wander away and get lost (magnetic contacts
must be placed on critical doors and windows)
 leaves a water tap open and floods the room (water
sensors must be placed in critical places)
 forgets something on the stove while cooking and
causes a fire (smoke detection sensors must be
placed in critical places)
 gets out of bed during the night and does not come
back within a specified time interval (bed-occupancy
sensor and configurable time control)
 never goes to the bathroom in 24 h (passive infrared
sensor and configurable time control)
 never opens refrigerator door in 24 h (magnetic
contact and configurable time control)
Depending on the personal choice of the person with
dementia and/or their caregiver, the kit will also:
 automatically turn on a light to help avoid a fall (via
a bed-occupancy sensor, passive infrared sensors and
Fig. 2 Concept of the monitoring kit used in the project
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automatic lights) when the person gets out of bed
during the night
 alert the caregiver when the temperature in the
house falls or rises excessively (temperature sensor
with configurable threshold)
 act as burglar alarm in some areas of the home (via
magnetic contacts and passive infrared sensors)
Installation and usability requirements
The installation of the home monitoring kit will be sim-
ple and quick because the dyads participating in the
intervention are particularly vulnerable. A checklist will
be created for the handymen performing the installation,
thus reducing the variability of their intervention in the
homes. Wireless communications and battery power will
be used for all of the sensors in the kit. The installation
of the kit will not be invasive as people with dementia
could get confused by the sensors. Components will be
hidden whenever possible in accordance with the choices
of the study participants (both people with dementia and
their caregivers). The home monitoring kits will also be
easy to use, so the dyads will only be trained to perform
simple procedures such as activating the device. In order
to achieve this, only a few buttons will be available on the
control unit with simple LED lights to indicate the state of
the control functions and the correct running state of the
home monitoring kit. Activation and deactivation of some
functions will also be available through text messaging. A
phone number will be available for the people with
dementia and their caregivers in case they need technical
assistance with the equipment after the home installation.
Technicians will be able to provide assistance remotely in
most cases.
Security requirements
One of the study goals is to assess the impact on care
burden and anxiety among informal caregivers through
the use of technology. In order to do this, false alarms
will be avoided as much as possible for the same rea-
sons. In the case of potentially dangerous situations,
such as a fire or water leakage, the system will emit an
acoustic alarm in accordance with the choices of the
person with dementia and their family. Any other type
of acoustic signal will be avoided so as not to frighten
the users or cause confusion.
Primary and secondary outcomes
The primary outcome of the study is the amount of
informal care support provided to the individual with
dementia by the primary informal caregiver.
Secondary outcomes of the study include:
1. Quality of life of the person with dementia
2. Fear of falling of the person with dementia
3. Caregiver health-related quality of life
4. Caregiver anxiety
5. Caregiver burden
6. The incidence of domestic accidents
7. The cost-effectiveness of the technological
intervention
Eligibility criteria
People with dementia living in the area of Region Skåne
(Southern Sweden), together with their primary informal
caregiver will be invited to participate in the study.
The inclusion criteria for the study that are applied to
the person with dementia are:
 a diagnosis of major neurocognitive disorders with
mild to moderate severity (Diagnostic and Statistical
Manual of Mental Disorders, version 5 (DSM-5))
following the new diagnostic criteria of the
American Psychiatric Association [23]
 a score of between 14 and 24 on the Mini Mental
State Examination (MMSE-SR)
 a score of between 1 and 5 on the Global
Deterioration Scale (GDS) [24]
 community dwelling
 able to speak and understand Swedish
 have at least one informal caregiver
Those not meeting the inclusion criteria will not be
eligible for the trial. In addition, specific exclusion cri-
teria will be:
 lack of informed consent
 being fully dependent on caregiver support for the
activities of daily living (ADL)
 presence of severe diseases associated with a life
expectancy of less than 6 months
 intention of moving to institutionalized care during
the study period
 unwillingness to use technological devices for home
assistance and safety
 being enrolled in another ongoing trial
 substance use disorder (DSM-5)
Informal caregivers are defined as those people who
provide care and support to an individual with dementia
on a regular basis without any form of financial compen-
sation. Exclusion criteria applied to the informal care-
giver are:
 lack of informed consent
 unwillingness to use technological devices for home
assistance and safety
 presence of severe diseases associated with a life
expectancy of less than 6 months
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 being already enrolled in another ongoing trial
The person with dementia and their caregiver can
either be cohabitating or live in different homes.
Informed consent will be actively sought from both
parties. Participation in the study is completely voluntary
and participants will receive verbal and written informa-
tion about the study prior to their participation and during
the study implementation.
Screening and recruitment
Participants will be recruited at the Memory Clinic at
Ängelholm’s Hospital in Sweden, which is coordinated
by PJ. The neurologists and nurses working at the Mem-
ory Clinic will review their list of patients to identify
those meeting the inclusion criteria and send an invita-
tion letter to participate that also describes the aims and
characteristics of the study. We estimated a participation
rate of 50% based on previous studies in this area [25].
In addition, we plan to distribute a brochure describing
the characteristics of the project among the primary
health care centers in the surrounding areas, informing
potential candidates about the study. The potential par-
ticipants (both people with dementia and their care-
givers) will then be assessed by the dementia nurse
coordinating the field activities (CDB) to double-check
whether the inclusion criteria are met and to further
assess the exclusion criteria. Eligible dyads will then be
asked to sign the informed consent for the study. Basic
information (age gender and town of residence) about
those participating in the study will be compared with
that of the people meeting the inclusion criteria who are
enlisted in the Memory Clinic database, only on aggregate
level, for the purpose to assess potential participation bias.
Randomization and allocation
Following written informed consent, names of the dyads
enrolled will be sent directly to the principal investigator
of the study (CC) who will perform the randomization.
Dyads will be randomized (according to a 1:1 ratio)
either to the experimental arm (receiving the techno-
logical intervention), or to the control arm (receiving
usual care). The allocation sequence will be generated
using the statistical software STATA (StataCorp, College
Station, TX, USA).
Assessments and procedures for data collection
All participants signing the informed consent to participate
will be enrolled in the study and will receive three home
visits by a dementia nurse trained in the methodology used
in the project. Informed consent will be actively sought
both from people with dementia and their caregivers. In
case of people declared legally incompetent, informed con-
sent will be requested from a family member or from
another person legally appointed by a judge to act as
substitute. Home visits will occur at enrollment and
after 3 and 12 months. Before the home visit, the
self-administered sections of the questionnaires will
be mailed to the caregivers participating in the study.
The home visits will take approximately 1 h, during
which the remaining sections of the questionnaire will
be administered to the study participants and a general
check of the self-administered forms will be made by the
dementia nurse. Those in the experimental arm will re-
ceive the installation of the home monitoring kit at latest
1 month following the baseline home visit.
A 12-section study-specific questionnaire has been de-
signed. The questionnaire sections addressing the people
with dementia will be administered by the dementia
nurse and cover the following domains: (A) sociodemo-
graphic information, (B) cognitive function, (C) ADL,
(D) health and quality of life, and (E) use of health care
resources.
The sections addressing the informal caregiver will be
self-administered and cover the following domains: (F)
sociodemographic information, (G) lifestyle, (H) health
and quality of life, (I) mental health and wellbeing, (J)
caregiver burden, (K) caregiving time, and (L) use of
health care resources.
Primary outcome measurement
The amount of informal care provided by caregivers to
the people with dementia, considered as a proxy of the
caregiver burden, will be measured in h/week and assessed
using a specific section of the Resource Utilization in De-
mentia (RUD) instrument [26]. The change from baseline
to months 3 and 12 will be considered as primary out-
come for the analysis.
Secondary outcome measurement
Quality of life of the person with dementia will be mea-
sured using the Quality Of Life in Alzheimer’s Disease
(QOL-AD) instrument [27], which has been developed
in collaboration with caretakers, caregivers and experts
in dementia care to ensure validity. Previous studies sug-
gest that the instrument’s validity and reliability are sat-
isfactory in a study population of people with dementia:
Cronbach’s α ranges from 0.84 to 0.88 for people with
dementia and caregivers and 1-week test-retest reliability
is also acceptable (intraclass correlation coefficient
(ICC) = 0.76 for people with dementia and 0.92 for care-
givers) [28].
Fear of falling of the person with dementia will be mea-
sured using the 16-item Falls Efficacy Scale-International
(FES-I) [29–31]. The evaluation of the Swedish version of
the instrument showed high internal reliability (Cronbach’s
α = 0.95) and an interitem correlation averaging 0.55 [32].
Quality of life of the caregiver will be assessed using the
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EuroQol, 5 dimensions, 3 levels (EQ-5D-3 L) health survey.
This standardized instrument to measure health outcomes
[33] has been used and validated in previous Swedish
studies [34, 35], showing both a good internal reliabil-
ity (Cronbach’s α = 0.73) and validity [36]. Caregiver
anxiety will be assessed using the anxiety component
of the Hospital Anxiety and Depression Scale (HADS)
[37]. HADS is a 14-item scale; seven of the items re-
late to anxiety and seven relate to depression; each
item is a Likert scale rated from 0 to 3, and this
means that the overall score for either anxiety or de-
pression will range from 0 to 21. Cronbach’s α for
HADS-Anxiety varies from 0.68 to 0.93 (mean 0.83)
and for HADS-Depression from 0.67 to 0.90 (mean
0.82) [38]. The Zarit Burden Inventory (ZBI) will be
used to measure the level of caregiver burden [38].
This is the instrument most consistently used in de-
mentia caregiving research [39], and it is often used
to measure the change of caregiver burden over time,
resulting from the progression of the disease severity
of the care recipient or from interventions aimed at
reducing burden. The revised version of the ZBI with
22 items will be used, as this has shown both a high
reliability (Cronbach’s α from 0.88 to 0.91) and valid-
ity (it is highly correlated with a single global burden
rating, r = 0.71) [40]. Domestic accidents are defined
as accidental falls, bruises, cuts, episodes of wander-
ing outside the home, burns and fires, flooding, or
other events which potentially or concretely harm the
people with dementia. The incidence of domestic
accidents will be assessed using an ad-hoc form.
Other measurements and adverse events
Basic social and demographic data, such as age, sex,
marital status, place of living, housing characteristics, in-
come, education and current and previous employments,
will be collected from both the people with dementia
and their informal caregivers. Information regarding al-
cohol use, smoking, physical exercise and diet of the
caregiver will be retrieved using an ad-hoc module based
on the forms of the Swedish National Health Survey.
The questionnaire developed for the study includes
other instruments that have already been tested in stud-
ies addressing people with dementia. To assess the func-
tional status of the people with dementia (dependency in
both personal and instrumental activities of daily living
(IADL)), the instruments of the interRAI suite will be
used. As the full form of the RUD questionnaire will be
administered, full information about use of health care
services, medications, and other characteristics of the
caregiving relationship will be available.
Although TECH@HOME is a nonpharmacological trial,
the research team will actively monitor adverse events, i.e.,
any unfavorable and unintended sign, symptom, or disease
temporally associated with the intervention, whether or
not it is causally related to the study (e.g., falls, acute epi-
sodes of illness, etc.). This will mainly be done using two
sources of information: (1) people with dementia and their
caregivers will be instructed to refer to the clinical study
coordinator in case of serious adverse events (requiring
general practitioner support or hospital care) and (2) simi-
larly, the clinical staff at the memory clinic will report in
case any adverse event is acknowledged. Participants (both
people with dementia and their caregivers) may be asked
to withdraw if it is determined that participation in the
trial does not represent the best interests of the partici-
pants themselves.
Sample size calculation and statistics
According to Nordberg and colleagues [5], the mean
number of hours spent in caregiving by informal care-
givers of people with dementia ranges from 7.7 h per
week (people with clinical dementia rating (CDR) 0.5) to
46.9 h per week (people with CDR 2.0). Wimo and col-
leagues [41] suggest that a standard deviation (SD) of 20
can be considered acceptable when using informal care-
giving hours as an outcome for formal sample size calcu-
lation. Given these numbers, a sample size of 320 dyads
randomized in a 1:1 ratio (160 per arm) is sufficient to
detect a mean decrease in caregiving time of 1 h per day
with a statistical power of 0.8 and a dropout rate of 20%,
aiming at a final number of 128 dyads in the experimen-
tal arm and 128 dyads in the control arm.
The final database will be checked and cleaned using
statistical routines after completion of each wave of as-
sessments. All modifications made during this phase will
be recorded in a specific file in order to allow for replic-
ability of all operations made on the raw database.
All collected data will be made anonymous in accord-
ance with the Swedish Data Protection Act (1998: 204)
and coded in a database with access protection. The
database will be stored on a server with continuous daily
safety backup. Researchers will analyze data containing
serial number encoded data without access to names or
social security numbers. All information relating to the
participants, the sampling framework, written consent,
and the results from questionnaires are handled so that
no unauthorized access to them can occur, and kept
locked up. Only current researchers in the project will
get access to the materials. Materials will be archived for
10 years.
The first step of the analysis will be exploratory in na-
ture. A descriptive analysis of the sample will be con-
ducted using univariate and bivariate statistical analyses
with the aim of verifying the comparability of the study
groups. Significant differences between exposures and
outcomes will be compared using the chi-square test,
Fisher’s exact test (in the case of categorical variables),
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the Mann-Whitney U test (for ordinal data such as the
FES-I), the t test, or analysis of variance (ANOVA) test
(for comparisons of continuous variables between
groups according to a normal or non-normal distribu-
tion). Additionally, to check possible selection bias, the
characteristics of the subjects in the sample will be com-
pared, only on aggregate level, to those of the population
with neurocognitive disorders included in the memory
clinic register of the study area (e.g., age, sex, and place
of living).
The primary outcome “time of informal care provided”
will be compared between the two groups using analysis
of covariance (ANCOVA). The analyses will be adjusted
for variables which are nonhomogenously distributed in
the two groups and controlling for other factors that the
medical literature suggests are associated with the two
outcomes (e.g., sex and age of caregivers, severity of
dementia, and use of private care workers). The analyses
of outcomes will be intention-to-treat (ITT).
Economic evaluation
Among the secondary outcomes of the study, we will
investigate the cost-effectiveness of the technological
intervention, in case the overall intervention does not
yield statistically significant improvements in the other
primary and secondary study outcomes. Therefore, cost
of illness, budget impact and cost-utility analyses will be
performed using the perspective of the National Health
Service [42] and in agreement with the ITT principle
per the CHEERS statement [43].
1. Cost of illness analysis (COI) will define the value of
the resources that are expended or foregone as a
result of dementia. The COI will consider separately
the perspective of the public health system, the users
and the society in order to describe in a more
comprehensive manner the real impact of the
disease in the study context
2. Budget impact analysis (BIA) will measure the net
cumulative effect of the technological intervention
for dementia in the Swedish population. If the
intervention can reduce the disease burden, it can
also assure a reduction in terms of
institutionalizations, number of hospitalization days,
drug consumption, caregiver burden, etc.
3. Cost-utility analysis (CUA): defined as the ratio
between the cost of the technological intervention
and the benefit it produces in terms of the number
of years lived in full health by the beneficiaries. The
result of the analysis will be an incremental cost per
quality-adjusted life year (QALY) gained.
Probabilistic sensitivity analyses (PSA) will also be per-
formed on the health economics models using the
software TreeAge Pro 2009. Results from the PSA will
also be presented as an acceptability curve, graphically
illustrating the probability of the intervention being cost
effective over a range of willingness-to-pay values.
Subgroup and secondary analyses
The implementation of a technological intervention can
be considered “complex” according to the definition of
the UK Medical Research Council [44]. This means that
the study researchers need to identify and appraise all
the intertwining components which are interacting and
determining the outcomes themselves. Therefore, spe-
cific subanalyses are planned such as intervention integ-
rity, dyad adherence to the study, and acceptance of the
technology by the users. The research group plans to
administer a further ad-hoc questionnaire at the end of
the trial to both the people with dementia and the care-
givers to assess their level of satisfaction with the tech-
nologies used. A specific ethical approval for this aspect
of the study will be sought in the future.
Handling of potential study bias
Risk of selection bias will be assessed by looking at the
results of the enrollment process. Clinical staff will be
instructed about how to explain, in very simple terms,
what participation in the trial will entail. This is ex-
pected to reduce refusals among those people who are
not very familiar with new technology. Considering the
high level of “digital” education among the older popula-
tion in Sweden, even compared to other Western coun-
tries, the likelihood of a selection bias should be
minimized. The involvement of expert dementia nurses
in the study also addresses the need to use research staff
with a high level of know-how on how to relate with
people with dementia and their families. This is also
expected to reduce the dropouts and withdrawals during
the study, thus increasing overall retention.
Other mediating and confounding variables might be
associated with study outcomes, and these could lead to
wrong/false results at the end of the trial. The use of a
multidimensional questionnaire and the randomization
process are expected to reduce such risks by providing
several covariates that will be available for the statistical
analyses to ensure the two study arms are comparable
under several social, clinical and functional profiles.
Last but not least, the lack of adherence to the technol-
ogy can constitute a major flaw for the study implementa-
tion and results. This risk will be minimized by using a
standardized but thorough approach to the training of
users (both people with dementia and their caregivers) with
technologies, by using a very simple technological device,
and by having the possibility to remotely monitor in real
time the actual use of the devices. The study coordinator
will be able to detect when a person is not using the
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technology and will promptly react in order to understand
(and possibly address) the reasons behind the lack of use.
Discussion
While the enormous technological progress made in
recent years has put technologies, such as mobile de-
vices and smart phones, in the reach of many, innovators
in dementia care are just starting to explore the full po-
tential of these developments to transform them into
valuable products and services for users. There is indeed
a lack of studies that evaluate the effectiveness and cost-
effectiveness of these new technologically enriched inter-
ventions designed for people with dementia. Previous
large-scale evaluations of the impact of telemedicine and
telecare, such as the Whole Demonstrator System in the
UK [45], did not include people with dementia despite
Alzheimer’s disease being one of the most burdensome
diseases in Europe [41].
This randomized controlled trial aims to evaluate the
effects of new technologies on caregiver burden by redu-
cing the time spent in supervision. The trial builds on
previous promising results from the UP-TECH project
in Italy [19]. The technologies used in TECH@HOME
will include similar, but improved, home monitoring kits
potentially leading to a greater impact on caregivers’ liv-
ing and care conditions. In addition, while the UP-
TECH study did not allow the researchers to estimate
the impact of the technology as a “stand-alone” interven-
tion (the monitoring kits were only given in combination
with case-management support), TECH@HOME will
overcome this limitation thanks to the possibility of
comparing a group of technology users versus nonusers.
Results from this intervention in dementia care in
Sweden hold the potential to inform regional and na-
tional policy-makers in Sweden and beyond.
Trial status
The trial started recruiting in March 2016 and the as-
sessments are scheduled to continue until December
2017.
Additional file
Additional file 1: Spirit Checklist. The additional file contains the
populated SPIRIT Checklist of the TECH@HOME study. (DOC 120 kb)
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